- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cadila Pharma unveils Fenticonazole Nitrate Vaginal Capsules to treat VVC
In a commitment to further strengthening the women’s healthcare portfolio Cadila’s Fenticad™ will be 35% more cost-effective and a drug of choice.
Ahmedabad: Ahmedabad-based Cadila Pharmaceuticals Limited has announced the launch of Fenticonazole Nitrate Vaginal Capsules for treatment of Vulvovaginal Candidiasis (VVC) under the brand name Fenticad™.
In a commitment to further strengthening the women's healthcare portfolio Cadila's Fenticad™ will be 35% more cost-effective and a drug of choice. Fenticad™ will be made available in 600 mg tablets.
VVC affects up to 75% of women once in their lifetime and severely impacts their quality of life. Almost 37% of women in rural India suffers from VVC in their reproductive age.* Itching (pruritus) and increased vaginal discharge are the most typical symptoms. Other symptoms are variable: soreness and burning, painful sexual intercourse (dyspareunia), or discomfort passing urine (dysuria). These symptoms may also occur in other vaginal infections.
A recent dipstick survey revealed that 36% of women went into social isolation when they were having VVC and 33% women admitted that symptoms of VVC impacted their self-confidence (Data on file).
Diabetes, pregnancy, inadequate intimate hygiene, unprotected and intense sexual activity, and antibiotic treatment can lead to high risk of developing VVC. During pregnancy, topical anti- fungal treatment (such as fenticonazole, clotrimazole, fluconazole) with the preparation of vaginal capsule or cream is preferred.
It has recently concluded and cleared USFDA inspection successfully in February 2020.
Read also: Cadila Pharma launches Hyperacidity drug Esomeprazole under brand name Esiloc in India
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751